Apc 002
Alternative Names: Apc-002Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Aptacure Therapeutics
- Class Antineoplastics; Nucleotide aptamers
- Mechanism of Action DKK1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Jan 2025 Aptacure Therapeutics plans to file for patent protection for Apc-002 in China (Aptacure pipeline, January 2025)
- 07 Jan 2025 Preclinical trials in Cancer in China (unspecified route) prior to January 2025 (Aptacure Therapeutics pipeline, January 2025)
- 07 Jan 2025 Aptacure Therapeutics plans to file for Orphan Drug Designation for Apc-002 (Aptacure pipeline, January 2025)